Nifty's recovery or just another trap? Analysts split on market's future direction!
Aurobindo Pharma is in focus.
· ET Stocks, Economic Times Markets
Nifty's recent recovery has generated optimism, but a sustained close above key resistance is crucial for further gains. Analysts suggest a cautious approach with potential accumulation of certain stocks during dips. Key stocks for investment include Aurobindo Pharma and TCS, which display strong price momentum and resilience.
The analysis
Against that, the stock is +2.9% on the day at ₹1,693.00, and has returned +6.7% over three months. It is trading close to its 52-week high, so expectations were already elevated going in. The pharma & healthcare sector has moved -1.0% over the same period, so Aurobindo Pharma is running 7.7 points ahead of its peers.
For Aurobindo Pharma, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Market context
- The company directly in focus is AUROPHARMA.
- Sector exposure: Pharma & Healthcare, IT.
- The immediate tone of coverage reads positive.
In this story
Related coverage
Upcoming dividend, stock split, bonus share, right issue next week, 12-17 October: Vedanta, TCS, Ola Electric, and more
Special dividend stocks: TCS, JSW Dulux, Premco Global, Honda India Power in 5 firms offering extra payout
Indias TCS senior staff will miss out on variable pay for September quarter, memo shows
IT stocks surge despite US immigration curbs
Corporate Actions This Week: TCS, Ola Electric, Anand Rathi & More In Focus | Full List